Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 86

Results For "scientific"

1210 News Found

ProBioGen co-develops new Freedom ExpiCHO-S cell line development kit
News | October 28, 2022

ProBioGen co-develops new Freedom ExpiCHO-S cell line development kit

It allows users to generate cell lines suitable for clinical development without their own starter cells, vectors or prior experience in the field.


USFDA Issues a CRL for the Biologics License Application for Insulin Aspart
Drug Approval | October 27, 2022

USFDA Issues a CRL for the Biologics License Application for Insulin Aspart

The CRL did not identify any outstanding scientific issues with the product.


ERES IV acquires a majority stake in Oncodesign Services
News | October 27, 2022

ERES IV acquires a majority stake in Oncodesign Services

Oncodesign Services (ODS ), with 600 clients in 33 countries and 227 employees worldwide, provides services from target identification to hit-to-lead and lead optimization through to IND filing.


AstraZeneca updates on the MESSINA Phase III trial for Fasenra in eosinophilic esophagitis
Clinical Trials | October 26, 2022

AstraZeneca updates on the MESSINA Phase III trial for Fasenra in eosinophilic esophagitis

High-level results from the MESSINA Phase III trial showed that AstraZeneca's Fasenra (benralizumab) did not meet one of the two dual-primary endpoints.


Parexel bags Global Customer Value Leadership Award
News | October 20, 2022

Parexel bags Global Customer Value Leadership Award

The award recognizes Parexel for delivering the best decentralized trial experience for customers through its capabilities, expertise, and patient recruitment and retention strategies


Mandaviya directs officials to focus on strengthening genome sequencing for early detection of variants
News | October 19, 2022

Mandaviya directs officials to focus on strengthening genome sequencing for early detection of variants

He also highlighted the need for community awareness for continued implementation of the Covid Appropriate Behaviour (CAB) especially in view of the upcoming festival season


Merck and the Bill & Melinda Gates Medical Research Institute announce licensing agreement for tuberculosis antibiotic candidates
News | October 19, 2022

Merck and the Bill & Melinda Gates Medical Research Institute announce licensing agreement for tuberculosis antibiotic candidates

The TBDA is a collaboration established among biopharmaceutical companies, research organizations and universities to accelerate the discovery and development of novel therapeutic candidates against TB.


Entod introduces high performance eye supplements & eye drops Eyecirque
Healthcare | October 11, 2022

Entod introduces high performance eye supplements & eye drops Eyecirque

The eyecirque under eye skin brightening supplement is a unique composition of scientifically proven essential antioxidants, vitamins and minerals


Merck announces positive top-line results from Phase 3 Stellar Trail evaluating Sotatercept for the treatment of PAH
Clinical Trials | October 11, 2022

Merck announces positive top-line results from Phase 3 Stellar Trail evaluating Sotatercept for the treatment of PAH

Sotatercept demonstrated significant improvement in exercise capacity and key secondary outcome measures compared to placebo when added to background therapy


AIIA signs MoU with AIST
Policy | October 09, 2022

AIIA signs MoU with AIST

The MoU will enable both countries to promote research collaboration and building capacities in the field of the Indian Ayurvedic system of traditional medicines